Linked Life Data

8427774

Source:http://linkedlifedata.com/resource/pubmed/id/8427774

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1993-3-10
pubmed:abstractText
A pilot study was undertaken to determine the feasibility of infusing 131I labelled monoclonal antibodies (MoAbs) into either the cavity remaining after resection of malignant glioma or into glioma cysts. Of the seven patients recruited into the study, two had cystic lesions and five resection cavities. Six of the seven were treated after relapse from primary therapy. All patients apart from one, were given a single injection of 131I conjugated to a MoAb (ERIC-1) recognising the human neural cell adhesion molecule (NCAM). One patient received a further injection of 131I-MoAb after regrowth of their disease. Pharmacokinetic studies revealed that the MoAb remained predominantly in the tumour cavity with little leakage into the systemic compartment. This resulted in a high calculated dose of radiation being delivered to the tumour cells either lining or within close proximity to the cavity/cyst wall. In such a small study, it is not possible to determine accurately response rates, but individual patient responses were observed. This, along with the low toxicity noted, demonstrates the feasibility of using 131I-MoAbs in this way. With 131I, radiation dose is deposited in tissue to a depth of 1 mm from the source. The possibility of applying isotopes such as 90Yttrium which will irradiate tumour/tissue to a greater depth (6 mm) is discussed in context with the biology of glioma infiltration into normal brain parenchyma.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8427774-1678003, http://linkedlifedata.com/resource/pubmed/commentcorrection/8427774-1895159, http://linkedlifedata.com/resource/pubmed/commentcorrection/8427774-2025571, http://linkedlifedata.com/resource/pubmed/commentcorrection/8427774-2033428, http://linkedlifedata.com/resource/pubmed/commentcorrection/8427774-2223581, http://linkedlifedata.com/resource/pubmed/commentcorrection/8427774-2230887, http://linkedlifedata.com/resource/pubmed/commentcorrection/8427774-2292138, http://linkedlifedata.com/resource/pubmed/commentcorrection/8427774-2297725, http://linkedlifedata.com/resource/pubmed/commentcorrection/8427774-2841267, http://linkedlifedata.com/resource/pubmed/commentcorrection/8427774-3334993, http://linkedlifedata.com/resource/pubmed/commentcorrection/8427774-3338052, http://linkedlifedata.com/resource/pubmed/commentcorrection/8427774-6086763, http://linkedlifedata.com/resource/pubmed/commentcorrection/8427774-637870, http://linkedlifedata.com/resource/pubmed/commentcorrection/8427774-6492045
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
67
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
144-51
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry.
pubmed:affiliation
Imperial Cancer Research Fund, Frenchay Hospital, Bristol, UK.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't